Remove FDA Approval Remove Gene Remove Gene Editing Remove Genetic Engineering
article thumbnail

Colorectal Cancer Awareness Month 2024: Innovations in Treatment

XTalks

Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. For example, gene editing can possibly be used to correct cancer-causing mutations or enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy.

article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

Clinical interest in bsAbs gained momentum following the promising data and market success of blinatumomab (BLINCYTO®, Amgen), a fragment-based bispecific T cell engager (BiTE), which first received FDA approval in 2014 and EMA approval in 2015.